CA3045567A1 - Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof - Google Patents

Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof Download PDF

Info

Publication number
CA3045567A1
CA3045567A1 CA3045567A CA3045567A CA3045567A1 CA 3045567 A1 CA3045567 A1 CA 3045567A1 CA 3045567 A CA3045567 A CA 3045567A CA 3045567 A CA3045567 A CA 3045567A CA 3045567 A1 CA3045567 A1 CA 3045567A1
Authority
CA
Canada
Prior art keywords
acetonitrile
cyclohexyl
pyridin
trans
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3045567A
Other languages
English (en)
French (fr)
Inventor
Jens Larsen
Mogens Larsen
Lars Kyhn Rasmussen
Andreas Ritzen
Tine Marianne DUUS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aqilion AB
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of CA3045567A1 publication Critical patent/CA3045567A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3045567A 2017-01-11 2018-01-10 Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof Pending CA3045567A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17151020 2017-01-11
EP17151020.9 2017-01-11
PCT/EP2018/050548 WO2018130563A1 (en) 2017-01-11 2018-01-10 Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
CA3045567A1 true CA3045567A1 (en) 2018-07-19

Family

ID=57777557

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3045567A Pending CA3045567A1 (en) 2017-01-11 2018-01-10 Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Country Status (25)

Country Link
US (1) US10703751B2 (enExample)
EP (1) EP3568396B1 (enExample)
JP (1) JP7009504B2 (enExample)
KR (1) KR102548543B1 (enExample)
CN (1) CN110167938B (enExample)
AU (1) AU2018208516B2 (enExample)
CA (1) CA3045567A1 (enExample)
CY (1) CY1123864T1 (enExample)
DK (1) DK3568396T3 (enExample)
ES (1) ES2846741T3 (enExample)
HR (1) HRP20210095T1 (enExample)
HU (1) HUE052720T2 (enExample)
IL (1) IL267829B (enExample)
LT (1) LT3568396T (enExample)
MX (1) MX389378B (enExample)
MY (1) MY195576A (enExample)
PL (1) PL3568396T3 (enExample)
PT (1) PT3568396T (enExample)
RS (1) RS61317B1 (enExample)
RU (1) RU2019125177A (enExample)
SI (1) SI3568396T1 (enExample)
TW (1) TWI760419B (enExample)
UA (1) UA123972C2 (enExample)
WO (1) WO2018130563A1 (enExample)
ZA (1) ZA201904190B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
MX2022004474A (es) 2016-12-16 2023-08-15 Janssen Pharmaceutica Nv Inhibidores de moléculas pequeñas de la familia de quinasas jak.
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2020007698A1 (en) * 2018-07-06 2020-01-09 Leo Pharma A/S Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof
JP7345220B2 (ja) * 2019-08-30 2023-09-15 ティーエスディー ライフ サイエンス カンパニー リミテッド イミダゾピリジン誘導体及びこれを有効成分として含有する薬学的組成物
US12390451B2 (en) 2021-03-11 2025-08-19 Janssen Pharmaceutica Nv Small molecule inhibitor of the JAK family of kinases
CN119569971B (zh) * 2025-02-07 2025-05-27 吉林大学 一种用于蛋白质磷酸化和棕榈酰化修饰同时筛选的Janus材料的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100375A1 (en) * 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
CN102712640A (zh) 2010-01-12 2012-10-03 弗·哈夫曼-拉罗切有限公司 三环杂环化合物、其组合物和应用方法
SG10201505997TA (en) * 2010-08-05 2015-09-29 Amgen Inc Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
UY34616A (es) 2012-02-10 2013-09-30 Galapagos Nv Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
EP3181564B1 (en) * 2012-11-20 2019-09-18 H. Hoffnabb-La Roche Ag Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
CN104098563A (zh) 2013-04-02 2014-10-15 山东亨利医药科技有限责任公司 Jnk抑制剂化合物
SG11201609016VA (en) 2014-04-30 2016-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
EA201990523A1 (ru) 2016-10-03 2019-10-31 НОВЫЕ СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Jak1 И ИХ ПРИМЕНЕНИЕ
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز

Also Published As

Publication number Publication date
NZ754922A (en) 2025-11-28
JP2020504186A (ja) 2020-02-06
TWI760419B (zh) 2022-04-11
CN110167938A (zh) 2019-08-23
BR112019014191A2 (pt) 2020-02-11
IL267829A (en) 2019-09-26
HRP20210095T1 (hr) 2021-03-05
MX389378B (es) 2025-03-20
RU2019125177A (ru) 2021-02-15
ES2846741T3 (es) 2021-07-29
MY195576A (en) 2023-02-02
PL3568396T3 (pl) 2021-05-31
US20190367512A1 (en) 2019-12-05
DK3568396T3 (da) 2021-01-18
WO2018130563A1 (en) 2018-07-19
EP3568396A1 (en) 2019-11-20
KR102548543B1 (ko) 2023-06-29
PT3568396T (pt) 2021-02-09
AU2018208516B2 (en) 2021-07-08
LT3568396T (lt) 2021-02-10
CY1123864T1 (el) 2022-05-27
TW201829407A (zh) 2018-08-16
IL267829B (en) 2022-02-01
US10703751B2 (en) 2020-07-07
EP3568396B1 (en) 2020-11-11
ZA201904190B (en) 2020-10-28
RU2019125177A3 (enExample) 2021-05-11
KR20190103231A (ko) 2019-09-04
SI3568396T1 (sl) 2021-04-30
RS61317B1 (sr) 2021-02-26
HUE052720T2 (hu) 2021-05-28
JP7009504B2 (ja) 2022-01-25
AU2018208516A1 (en) 2019-07-11
CN110167938B (zh) 2024-06-14
MX2019008331A (es) 2020-01-14
UA123972C2 (uk) 2021-06-30

Similar Documents

Publication Publication Date Title
AU2018208516B2 (en) Novel amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof
JP7248256B2 (ja) Ｊａｋキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用
US10851116B2 (en) Bicyclic amines as novel JAK kinase inhibitors
TW201309703A (zh) 作為蛋白質酪胺酸激酶抑制劑之新穎磺醯胺哌□衍生物及其醫藥用途
EP3576743B1 (en) 5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2 5]octane-8-carboxylic acid derivatives as jak kinase inhibitors
EP3818060B1 (en) Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof
BR112019014191B1 (pt) Composto e composição farmacêutica
HK40013317A (en) Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
KR102539761B1 (ko) 2-티옥소티아졸리딘-4-온 유도체 화합물 및 이의 용도
AU2019278104B2 (en) JAK3 selective inhibitor
HK40013317B (en) Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
WO2025151602A1 (en) Heteroaryl compounds as ligand directed degraders of irak4
EP4698531A1 (en) Pyrrolopyrazine compounds, preparation thereof and therapeutic uses thereof
CA3159250A1 (en) New compounds for treatment of diseases related to dux4 expression
WO2020035557A1 (en) Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20221221

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240812

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241218

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241218

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250102

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250405

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250405

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250527

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250610

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250611

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250724

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250724

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251202

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260302

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260302